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Tuberculosis (TB) remains the single largest
infectious disease causing high mortality in humans,
leading to 3 million deaths annually, about five deaths
every minute.  Approximately 8-10 million people
are infected with this pathogen every year1. Out of
the total number of cases, 40 per cent of cases are
accommodated in South East Asia alone.  In India,
there are about 500,000 deaths occurring annually
due to TB2, with the incidence and prevalence being
1.5 and 3.5 millions per year.
This review summarizes the information available
on host immune response to the causative bacteria,
complexity of host-pathogen interaction and
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Tuberculosis is a major health problem throughout the world causing large number of deaths,
more than that from any other single infectious disease. The review attempts to summarize the
information available on host immune response to Mycobacterium tuberculosis. Since the main
route of entry of the causative agent is the respiratory route, alveolar macrophages are the
important cell types, which combat the pathogen. Various aspects of macrophage-mycobacterium
interactions and the role of macrophage in host response such as binding of M. tuberculosis to
macrophages via surface receptors, phagosome-lysosome fusion, mycobacterial growth
inhibition/killing through free radical based mechanisms such as reactive oxygen and nitrogen
intermediates; cytokine-mediated mechanisms; recruitment of accessory immune cells for local
inflammatory response and presentation of antigens to T cells for development of acquired
immunity have been described. The role of macrophage apoptosis in containing the growth of
the bacilli  is also discussed. The role of other components of innate immune response such as
natural resistance associated macrophage protein (Nramp), neutrophils, and natural killer cells
has been discussed. The specific acquired immune response through CD4 T cells, mainly
responsible for protective Th1 cytokines and through CD8 cells bringing about cytotoxicity,
also has been described.  The role of CD-1 restricted CD8+ T cells and non-MHC restricted γ/δ
T cells has been described although it is incompletely understood at the present time. Humoral
immune response is seen though not implicated in protection. The value of cytokine therapy
has also been reviewed. Influence of the host human leucocyte antigens (HLA) on the
susceptibility to disease is discussed.
Mycobacteria are endowed with mechanisms through which they can evade the onslaught of
host defense response. These mechanisms are discussed including diminishing the ability of
antigen presenting cells to present antigens to CD4+ T cells; production of suppressive cytokines;
escape from fused phagosomes and inducing T cell apoptosis.
The review brings out the complexity of the host-pathogen interaction and underlines the
importance of identifying the mechanisms involved in protection, in order to design vaccine
strategies and find out surrogate markers to be measured as in vitro correlate of protective
immunity.
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Pathogenesis of TB
Route and site of infection: Mycobacterium
tuberculosis is an obligatory aerobic, intracellular
pathogen, which has a predilection for the lung tissue
rich in oxygen supply.  The tubercle bacilli enter  the
body  via the respiratory route.  The bacilli spread
from the site of initial infection in the lung through
the lymphatics or blood to other parts of the body,
the apex of the lung and the regional lymph node
being favoured sites.  Extrapulmonary TB of the
pleura, lymphatics, bone, genito-urinary system,
meninges, peritoneum, or skin occurs in about 15 per
cent of TB patients.
Events following entry of bacilli: Phagocytosis of M.
tuberculosis by alveolar macrophages is the first
event in the host-pathogen relationship that decides
outcome of  infection. Within 2 to 6 wk of infection,
cell-mediated immunity (CMI) develops, and there
is an influx of lymphocytes and activated
macrophages into the lesion resulting in granuloma
formation.  The exponential growth of the bacilli is
checked and dead macrophages form a caseum.  The
bacilli are contained in the caseous centers of the
granuloma.  The bacilli may remain forever within
the granuloma, get re-activated later or may get
discharged into the airways after enormous increase
in number, necrosis of bronchi and cavitation.
Fibrosis represents the last-ditch defense mechanism
of the host, where it occurs surrounding a central area
of necrosis to wall off the infection when all other
mechanisms failed. In our laboratory, in guineapigs
infected with M. tuberculosis, collagen, elastin and
hexosamines showed an initial decrease followed by
an increase in level. Collagen stainable by Van
Gieson’s method was found to be increased in the
lung from the 4th wk onwards3.
Macrophage-Mycobacterium interactions and the
role of macrophage in host response can be
summarized under the following headings: surface
binding of M. tuberculosis  to macrophages;
phagosome-lysosome fusion; mycobacterial growth
inhibition/killing; recruitment of accessory immune
cells for local inflammatory response and
presentation of antigens to T cells for development
of acquired immunity.
Binding of M. tuberculosis to monocytes /
macrophages: Complement receptors (CR1, CR2,
CR3 and CR4), mannose receptors (MR) and other
cell surface receptor molecules play an important role
in binding of the organisms to the phagocytes4.  The
interaction between MR on phagocytic cells and
mycobacteria seems to be mediated through the
mycobacterial surface glycoprotein
lipoarabinomannan (LAM)5.  Prostaglandin E2
(PGE2) and interleukin (IL)-4, a Th2-type cytokine,
upregulate CR and MR receptor expression and
function, and interferon-γ (IFN-γ) decreases the
receptor expression, resulting in  diminished ability
of the mycobacteria to adhere to macrophages6.
There is also a role for surfactant protein receptors,
CD14 receptor7 and the scavenger receptors in
mediating bacterial binding8.
Phagolysosome fusion : Phagocytosed
microorganisms are subject to degradation by
intralysosomal acidic hydrolases upon
phagolysosome fusion9.  This highly regulated event10
constitutes a significant antimicrobial mechanism of
phagocytes. Hart et al11 hypothesized that prevention
of phagolysosomal fusion is a mechanism by which
M. tuberculosis survives inside macrophages11. It has
been reported that mycobacterial sulphatides12,
derivatives of multiacylated trehalose 2-sulphate13,
have the ability to inhibit phagolysosomal fusion.  In
vitro studies demonstrated that M. tuberculosis
generates copious amounts of ammonia in cultures,
which is thought to be responsible for the inhibitory
effect14.
How do the macrophages handle the engulfed M.
tuberculosis?: Many antimycobacterial effector
functions of macrophages such as generation of
reactive oxygen intermediates (ROI), reactive
nitrogen intermediates (RNI), mechanisms mediated
by cytokines, have been described.
Reactive oxygen intermediates (ROI): Hydrogen
peroxide (H2O2), one of the ROI generated by
macrophages via the oxidative burst, was the first
identified effector molecule that mediated
mycobactericidal effects of mononuclear
phagocytes15.  However, the ability of ROI to kill M.
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tuberculosis has been demonstrated only in mice16
and remains to be confirmed in humans. Studies
carried out in our laboratory have shown that M.
tuberculosis infection induces the accumulation of
macrophages in the lung and also H2O2 production17.
Similar local immune response in tuberculous ascitic
fluid has also been demonstrated18. However, the
increased production of hydrogen peroxide by
alveolar macrophages is not specific for TB19.
Moreover, the alveolar macrophages produced less
H2O2 than the corresponding blood monocytes.
Reactive nitrogen intermediates (RNI): Phagocytes,
upon activation by IFN-γ and tumor necrosis factor-
α (TNF-α), generate nitric oxide (NO) and related
RNI via inducible nitric oxide synthase (iNOS2)
using L-arginine as the substrate.  The significance
of these toxic nitrogen oxides in host defense against
M. tuberculosis has been well documented, both in
vitro and in vivo, particularly in the murine system20.
In genetically altered iNOS gene knock-out (GKO)
mice M. tuberculosis replicates much faster than in
wild type animals, implying a significant role for NO
in mycobacterial host defense21.
In our study, rat peritoneal macrophages were
infected in vitro with M. tuberculosis and their fate
inside macrophages was monitored. Alteration in the
levels of NO, H2O2 and lysosomal enzymes such as
acid phosphatase, cathepsin-D and β-glucuronidase
was also studied. Elevation in the levels of nitrite
was observed along with the increase in the level of
acid phosphatase and β-glucuronidase. However,
these microbicidal agents did not alter the
intracellular viability of M. tuberculosis22.
The role of RNI in human infection is
controversial and differs from that of mice. 1, 25
dihydroxy vitamin D3 [1, 25-(OH)2D3] was reported
to induce the expression of the NOS2 and M.
tuberculosis inhibitory activity in the human HL-60
macrophage-like cell line23.  This observation thus
identifies NO and related RNI as the putative
antimycobacterial effectors produced by human
macrophages.  This notion is further supported by
another study in which IFN-γ stimulated human
macrophages co-cultured with lymphocytes (M.
tuberculosis  lysate/IFN-γ  primed) exhibited
mycobactericidal activity concomitant with the
expression of NOS224.  High level expression of
NOS2 has been detected immunohistochemically in
macrophages obtained by broncho alveolar lavage
(BAL) from individuals with active pulmonary TB25.
Other mechanisms of growth inhibition/killing: IFN-
γ and TNF-α mediated antimycobacterial effects have
been reported. In our laboratory studies, we were
unable to demonstrate mycobacterial killing in
presence of IFN-γ, TNF-α and a cocktail of other
stimulants26.There is lack of an experimental system
in which the killing of M. tuberculosis  by
macrophages can be reproducibly demonstrated in
vitro.  The reports of the effect of IFN-γ treated
human macrophages on the replication of M.
tuberculosis range from its being inhibitory27 to
enhancing28.  Later it was demonstrated that 1,25-
(OH)2D3, alone or in combination with IFN-γ and
TNF-α, was able to activate macrophages to inhibit
and/or kill M. tuberculosis in the human system29.
In our comparative study of immune response after
vaccination with BCG, in subjects from Chengalput,
India and London, M. bovis BCG vaccination did not
enhance bacteriostasis with the Indians, but did so
with the subjects from London.
Macrophage apoptosis
Another potential mechanism involved in
macrophage defense against M. tuberculosis is
apoptosis or programmed cell death.  Placido et al30
found that using the virulent strain H37Rv, apoptosis
was induced in a dose-dependent fashion in BAL cells
recovered from patients with TB, particularly in
macrophages from HIV-infected patients.  Klingler
et al31 have demonstrated that apoptosis associated
with TB is mediated through a downregulation of bcl-
2, an inhibitor of  apoptosis.  Within the granuloma,
apoptosis is prominent in the epithelioid cells as
demonstrated by condensed chromatin viewed by
light microscopy or with the in situ  terminal
transferase mediated nick end labeling (TUNEL)
technique32.
Molloy et al33 have shown that macrophage
apoptosis results in reduced viability of
mycobacteria.  The effects of Fas L- mediated or
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TNF-α-induced apoptosis on M. tuberculosis
viability in human and mouse macrophages is
controversial; some studies report reduced bacterial
numbers within macrophages after apoptosis34 and
others indicate this mechanism has little
antimycobacterial effect35.
Evasion of host immune response by M.
tuberculosis
M. tuberculosis is equipped with numerous
immune evasion strategies, including modulation of
antigen presentation to avoid elimination by T cells.
Protein secreted by M. tuberculosis  such as
superoxide dismutase and catalase are antagonistic
to ROI36.  Mycobacterial components such as
sulphatides, LAM and phenolic- glycolipid I (PGL-
I) are potent oxygen radical scavengers37,38.  M.
tuberculosis-infected macrophages appear to be
diminished in their ability to present antigens to CD4+
T cells, which  leads to persistent infection39.  Another
mechanism by which antigen presenting cells (APCs)
contribute to defective T cell proliferation and
function  is by the production of cytokines, including
TGF-β, IL-1040 or IL-641. In addition, it has also been
reported that virulent mycobacteria were able to
escape from fused phagosomes and multiply42.
Host immune mechanisms in TB
Innate immune response: The phagocytosis and the
subsequent secretion of IL-12 are processes initiated
in the absence of prior exposure to the antigen and
hence form a component of innate immunity.  The
other components of innate immunity are natural
resistance associated macrophage protein (Nramp),
neutrophils, natural killer cells (NK) etc. Our
previous work showed that plasma lysozyme and
other enzymes may play an important role in the first
line defense, of innate immunity to M. tuberculosis43.
The role of CD-1 restricted CD8+ T cells and non-
MHC restricted T cells have been implicated but
incompletely understood.
Nramp: Nramp is crucial in transporting nitrite from
intracellular compartments such as the cytosol to
more acidic environments like  phagolysosome,
where it can be converted to NO.  Defects in Nramp
production increase susceptibility to mycobacteria.
Newport et al44 studied a group of children with
susceptibility to mycobacterial infection and found
Nramp1 mutations as the cause for it. Our laboratory
study  on pulmonary and spinal TB patients and
control subjects suggested that NRAMP1 gene might
not be associated with the susceptibility to pulmonary
and spinal TB in the Indian population45.
Neutrophils: Increased accumulation of neutrophil in
the granuloma and increased chemotaxis has
suggested a role for neutrophils46.  At the site of
multiplication of bacilli, neutrophils are the first cells
to arrive followed by NK cells, γ/δ cells and α/β cells.
There is evidence to show that granulocyte-
macrophage-colony stimulating factor (GM-CSF)
enhances phagocytosis of bacteria by neutrophils47.
Human studies have demonstrated that neutrophils
provide agents such as defensins, which is lacking
for macrophage-mediated killing48. Majeed et al49
have shown that neutrophils can bring about killing
of M. tuberculosis in the presence of calcium under
in vivo conditions.
Natural killer (NK) cells: NK cells are also the
effector cells of innate immunity. These cells may
directly lyse the pathogens or can lyse infected
monocytes.  In vitro culture with live M. tuberculosis
brought about the expansion of NK cells implicating
that they may be important responders to  M.
tuberculosis  infection  in vivo50. During early
infection, NK cells are capable of activating
phagocytic cells at the site of infection. A significant
reduction in NK activity is associated with multidrug-
resistant TB (MDR-TB).  NK activity in BAL has
revealed that different types of pulmonary TB are
accompanied by varying degrees of depression51. IL-
2 activated NK cells can bring about
mycobactericidal activity in macrophages infected
with M. avium complex (MAC) as a non specific
response52.  Apoptosis is a likely mechanism of NK
cytotoxicity.  NK cells produce IFN-γ and can lyse
mycobacterium pulsed target cells53. Our studies54
demonstrate that lowered NK activity during TB
infection is probably the ‘effect’ and not the ‘cause’
for the disease as demonstrated by the follow up
study.  Augmentation of NK activity with cytokines
implicates them as potential adjuncts to TB
chemotherapy54.
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The Toll-like receptors (TLR): The recent discovery
of the importance of the TLR protein family in
immune responses in insects, plants and vertebrates
has provided new insight into the link between innate
and adaptive immunity.  Medzhitov et al55 showed
that a human homologue of the Drosophila Toll
protein signals activation of adaptive immunity.  The
interactions between M. tuberculosis and TLRs are
complex and it appears that distinct mycobacterial
components may interact with different members of
the TLR family. M. tuberculosis  can
immunologically activate cells via either TLR2 or
TLR4 in a CD 14-independent, ligand-specific
manner56.
Acquired immune response
Humoral immune response: Since M. tuberculosis is
an intracellular pathogen, the serum components may
not get access and may not play any protective role.
Although many researchers have dismissed a role for
B cells or antibody in protection against TB57, recent
studies suggest that these may contribute to the
response to TB58.
Mycobacterial antigens inducing humoral response
in humans have been studied, mainly with a view to
identify diagnostically relevant antigens.  Several protein
antigens of M. tuberculosis have been identified using
murine monoclonal antibodies59.  The immunodominant
antigens for mice include 71, 65, 38, 23, 19, 14 and 12
kDa proteins.  The major protein antigens of M. leprae
and M. tuberculosis have been cloned in vectors such
as Escherichia coli.  Not all the antigens identified based
on mouse immune response were useful to study human
immune response.
In our laboratory a number of M. tuberculosis
antigens  have been purified and used for diagnosis
of adult and childhood TB60-66. Combination of
antigens were also found to be useful in the diagnosis
of HIV-TB67,68. Detection of circulating immune
complex bound antibody was found to be more
sensitive as compared to serum antibodies. The
purified antigens were evaluated for their utility in
diagnosing infection69,70.
Cellular immune response
T cells: M. tuberculosis is a classic example of a
pathogen for which the protective response relies on
CMI.  In the mouse model, within 1 wk of infection
with virulent M. tuberculosis, the number of activated
CD4+ and CD8+ T cells in the lung draining lymph
nodes increases71.  Between 2 and 4 wk post-infection,
both CD4+ and CD8+ T cells migrate to the lungs and
demonstrate an effector/memory phenotype
(CD44hiCD45loCD62L-); approximately 50 per cent
of these cells are CD69+.  This indicates that activated
T cells migrate to the site of infection and are
interacting with APCs.  The tuberculous granulomas
contain both CD4+ and CD8+ T cells72 that contains
the infection within the granuloma and prevent
reactivation.
CD4 T cells:  M. tuberculosis resides primarily in a
vacuole within the macrophage, and thus, major
histocompatibility complex (MHC) class II
presentation of mycobacterial antigens to CD4+ T
cells is an obvious outcome of infection.  These cells
are most important in the protective response against
M. tuberculosis.  Murine studies with antibody
depletion of CD4+T cells73, adoptive transfer74, or the
use of gene-disrupted mice75 have shown that the
CD4+ T cell subset is required for control of infection.
In humans, the pathogenesis of HIV infection has
demonstrated that the loss of CD4+ T cells greatly
increases susceptibility to both acute and re-
activation TB76. The primary effector function of
CD4+ T cells is the production of IFN-γ and possibly
other cytokines, sufficient to activate macrophages.
In MHC class II-/- or CD4-/- mice, levels of IFN-γ
were severely diminished very early in infection75.
NOS2 expression by macrophages was also delayed
in the CD4+ T cell deficient mice, but returned to
wild type levels in conjunction with IFNγ
expression75.
In a murine model of chronic persistent M.
tuberculosis infection77, CD4 T cell depletion caused
rapid re-activation of the infection.  IFN-γ levels
overall were similar in the lungs of CD4+ T cell-
depleted and control mice, due to IFNγ production
by CD8+ T cells.  Moreover, there was no apparent
change in macrophage NOS2 production or activity
in the CD4+ T cell-depleted mice.  This indicated that
there are IFN-γ and NOS2-independent, CD4+ T cell-
dependent mechanisms for control of TB.  Apoptosis
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or lysis of infected cells by CD4+ T cells may also
play a role in controlling infection32. Therefore, other
functions of CD4+ T cells are likely to be important
in the protective response and must be understood as
correlates of immunity and as targets for vaccine
design.
CD8 T cells: CD8+ cells are also capable of secreting
cytokines such as IFN-γ and IL-4 and thus may play
a role in regulating the balance of Th1 and Th2 cells
in the lungs of patients with pulmonary TB. The
mechanism by which mycobacterial proteins gain
access to the MHC class I molecules is not fully
understood.  Bacilli in macrophages have been found
outside the phagosome 4-5 days after infection78, but
presentation of mycobacterial antigen by infected
macrophages to CD8 T cells can occur as early as 12
h after infection. Reports provide evidence for a
mycobacteria-induced pore or break in the vesicular
membrane surrounding the bacilli that might allow
mycobacterial antigen to enter the cytoplasm of the
infected cell79.
Yu et al80 analyzed CD4 and CD8 populations
from patients with rapid, slow, or intermediate
regression of disease while receiving therapy and
found that slow regression was associated with an
increase in CD8+ cells in the BAL.  Taha et al81 found
increased CD8+ T cells in the BAL of patients with
active TB, along with striking increases in the number
of BAL cells expressing IFNγ and IL-12 mRNA.
These studies point to a potential role for CD8+ T
cells in the immune response to TB. Lysis of infected
human dendritic cells and macrophages by CD1- and
MHC class I-restricted CD8+ T cells specific for M.
tuberculosis antigens reduced intracellular bacterial
numbers82.  The killing of intracellular bacteria was
dependent on perforin /granulysin83.  Lysis through
the Fas/Fas L pathway did not reproduce this effect82.
At high effector-to-target ratio (50:1), this lysis
reduced bacterial numbers84. It is shown that IFN-γ
production in the lungs by the CD8 T cell subset was
increased at least four-fold in the perforin deficient
(P-/-) mice, suggesting that a compensatory effect
protects P-/- mice from acute infection85.
Studies defining antigens recognized by CD8+ T
cells from infected hosts without active TB provide
attractive vaccine candidates and support the notion
that CD8+ T cell responses, as well as CD4+ T cell
responses must be stimulated to provide protective
immunity.
T cell apoptosis: A wide variety of pathogens can
attenuate CMI by inducing T cell apoptosis.
Emerging evidence indicates that apoptosis of T cells
does occur in murine86 and human TB87. In in vitro
studies using peripheral blood mononuclear cells
(PBMC) from tuberculous patients88, the phenomenon
of T cell hypo-responsiveness has been linked to
spontaneous or M. tuberculosis-induced apoptosis of
T cells.  The observed apoptosis is associated with
diminished M. tuberculosis-stimulated IFN-γ and IL-
2 production.  In tuberculous infection, CD95-
mediated Th1 depletion occurs, resulting in
attenuation of protective immunity against M.
tuberculosis ,  thereby enhancing disease
susceptibility89. Detailed analysis of para
formaldehyde-fixed human tuberculous tissues
revealed that apoptotic CD3+, CD45RO+ cells are
present in productive tuberculous granulomas,
particularly those harbouring a necrotic centre90.
Studies carried out in our laboratory have
demonstrated the ability of mycobacterial antigens
to bring about apoptosis in animal models91. In
addition, increased spontaneous apoptosis, which is
further enhanced by mycobacterial antigens, has also
been shown to occur in pleural fluid cells92.
Nonclassically restricted CD8 T cells: CD1
molecules are nonpolymorphic antigen presenting
molecules that present lipids or glycolipids to T cells.
There is evidence of a recall T cell response to a CD1-
restricted antigen in M. tuberculosis-exposed purified
protein derivative (PPD) positive subjects93.  CD1
molecules are usually found on dendritic cells in
vivo94, and dendritic cells present in the lungs may
be stimulating CD1-restricted cells in the granuloma
that can then have a bystander effect on infected
macrophages.  Further investigation of the processing
and presentation of mycobacterial antigens to CD1-
restricted CD8 T cells is necessary to understand the
potential contribution of this subset to protection.
γ/δ T-cells in TB: The role of γ/δ T cells in the
host response in TB has been incompletely worked
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out.  These cells are large granular lymphocytes that
can develop a dendritic morphology in lymphoid
tissues; some γ/δ T cells may be CD8+.  In general,
γ/δ T cells are felt to be non-MHC restricted and they
function largely as cytotoxic T cells.
Animal data suggest that γ/δ  cells play a
significant role in the host response to TB in mice
and in other species95, including humans. M.
tuberculosis reactive γ/δ T cells can be found in the
peripheral blood of tuberculin positive healthy
subjects and these cells are cytotoxic for monocytes
pulsed with mycobacterial antigens and  secrete
cytokines that may be involved in granuloma
formation96.  Studies97,98 demonstrated that γ/δ cells
were relatively more common (25 to 30% of the total)
in patients with protective immunity as compared to
patients with ineffective immunity.  Our study in
childhood TB patients showed that the proportion of
T cells expressing the γ/δ T cell receptor was similar
in TB patients and controls99.  Thus γ/δ  cells may
indeed play a role in early immune response against
TB and  is an important part of the protective
immunity in patients with latent infection100.
Th1 and Th2 dichotomy in TB: Two broad (possibly
overlapping) categories of T cells have been
described: Th1 type and Th2 type, based on the
pattern of cytokines they secrete, upon antigen
stimulation.  Th1 cells secrete IL-2, IFN-γ and play
a protective role in intracellular infections. Th2 type
cells secrete IL-4, IL-5 and IL-10 and are either
irrelevant or exert a negative influence on the immune
response. The balance between the  two types of
response is reflected in the resultant host resistance
against infection. The type of Th0 cells shows an
intermediate cytokine secretion pattern.  The
differentiation of Th1 and Th2 from these precursor
cells may be under the control of cytokines such as
IL-12.
In mice infected with virulent strain of M.
tuberculosis, initially Th1 like and later Th2 like
response has been demonstrated101. There are
inconsistent reports in literature on preponderance
of Th1 type of cytokines, of Th2 type, increase of
both, decrease of Th1, but not increase of Th2  etc.
Moreover, the response seems to vary between
peripheral blood and site of lesion; among the
different stages of the disease depending on the
severity.
It has been reported that PBMC from TB patients,
when stimulated in vitro with PPD, release lower
levels of IFN-γ and IL-2, as compared to tuberculin
positive healthy subjects102.  Other studies have also
reported reduced IFN-γ103 increased IL-4 secretion104
or increased number of IL-4 secreting cells105.  These
studies concluded that patients with TB had a Th2-
type response in their peripheral blood, whereas
tuberculin positive patients had a Th1-type response.
More recently, cellular response at the actual sites
of disease has been examined.  Zhang et al106 studied
cytokine production in pleural fluid and found high
levels of IL-12 after stimulation of pleural fluid cells
with M. tuberculosis.  IL-12 is known to induce a
Th1-type response in undifferentiated CD4+ cells and
hence there is a Th1 response at the actual site of
disease.  The same  group107 observed that TB patients
showed evidence of high IFNγ production and no IL-
4 secretion by the lymphocytes in the lymph nodes.
There was no enhancement of Th2 responses at the
site of disease in human TB.  Robinson et al108 found
increased levels of IFN-γ mRNA in situ in  BAL cells
from patients with active pulmonary TB.
In addition, reports suggest that in humans with
TB, the strength of the Th1-type immune response
relate directly to the clinical manifestations of the
disease. Sodhi et al109 have demonstrated that low
levels of circulating IFN-γ in peripheral blood were
associated with severe clinical TB.  Patients with
limited TB have an alveolar lymphocytosis in
infected regions of the lung and these lymphocytes
produce high levels of IFN-γ34.  In patients with far
advanced or cavitary disease, no Th1-type
lymphocytosis is present.
Cytokines
Interleukin-12 : IL-12 is induced following
phagocytosis of M. tuberculosis  bacilli by
macrophages and dendritic cells110, which leads to
development of a Th1 response with production of
IFN-γ. IL-12p40-gene deficient mice were susceptible
to infection and had increased bacterial burden, and
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decreased survival time, probably due to reduced IFN-
γ production111.  Humans with mutations in IL-12p40
or the IL-12R  genes present with reduced
IFN-γ  production from T cells and are more
susceptible to disseminated BCG and M. avium
infections112.  An intriguing study indicated that
administration of IL-12 DNA could substantially
reduce bacterial numbers in mice with a chronic M.
tuberculosis infection113, suggesting that induction
of this cytokine is an important factor in the design
of a TB vaccine.
McDyer et al114 found that stimulated PBMC from
MDR-TB patients had less secretion of IL-2 and IFN-
γ than did cells from healthy control subjects.  IFN-
γ production could be restored if PBMC were
supplemented with IL-12 prior to stimulation and
antibodies to IL-12 caused a further decrease in IFN-
γ upon stimulation.  Taha et al81 demonstrated that in
patients with drug susceptible active TB both IFN-γ
and IL-12 producing BAL cells were abundant as
compared with BAL cells from patients with inactive
TB.
Interferon-γ: IFN-γ, a key cytokine in control of M.
tuberculosis infection is produced by both CD4+ and
CD8+ T cells, as well as by NK cells.  IFN-γ might
augment antigen presentation, leading to recruitment
of CD4+ T-lymphocytes and/or cytotoxic T-
lymphocytes, which might participate in
mycobacterial killing. Although IFN-γ production
alone is insufficient to control M. tuberculosis
infection, it is required for the protective response to
this pathogen. IFN-γ is the major activator of
macrophages and it causes mouse but not human
macrophages to inhibit the growth of M. tuberculosis
in vitro16.  IL-4, IL-6 and GM-CSF could bring about
in vitro killing of mycobacteria by macrophages
either alone or in synergy with IFN-γ in the murine
system115.  IFN-γ GKO mice are most susceptible to
virulent M. tuberculosis116.
Humans defective in genes for IFN-γ or the IFN-
γ receptor are prone to serious mycobacterial
infections, including M. tuberculosis117.  Although
IFN-γ production may vary among subjects, some
studies suggest that IFN-γ levels are depressed in
patients with active TB107,118.   Another study
demonstrated that M. tuberculosis could prevent
macrophages from responding adequately to IFN-γ119.
This suggests that the amount of IFN-γ produced by
T cells may be less predictive of outcome than the
ability of the cells to respond to this cytokine.
Our study comparing the immune response to pre-
and post- BCG vaccination, has shown that BCG had
little effect in driving the immune response towards
IFN-γ and a protective Th1 response120. In another
study on tuberculous pleuritis, a condition which may
resolve without therapy, a protective Th1 type of
response with increased IFN-γ is seen at the site of
lesion (pleural fluid), while a Th0 type of response
with both IFN-γ and IL-4 is seen under in vitro
conditions121.
To determine if the manifestations of initial
infection with M. tuberculosis reflect changes in the
balance of T cell cytokines, we evaluated in vitro
cytokine production of children with TB and healthy
tuberculin reactors122. IFN-γ production was most
severely depressed in patients with moderately
advanced and far advanced pulmonary disease and
in malnourished patients. Production of IL-12, IL-4
and IL-10 was similar in TB patients and healthy
tuberculin reactors. These results indicate that the
initial immune response to M. tuberculosis  is
associated with diminished IFN-γ production, which
is not due to reduced production of IL-12 or enhanced
production of IL-4 or IL-10.
Tumor necrosis factor (TNF-α): TNF-α is believed
to play multiple roles in immune and pathologic
responses in TB. M. tuberculosis induces TNF-α
secretion by macrophages, dendritic cells and T cells.
In mice deficient in TNF-α or the TNF receptor, M.
tuberculosis infection resulted in rapid death of the
mice, with substantially higher bacterial burdens
compared to control mice123.  TNF-α in synergy with
IFN-γ induces NOS2 expression124.
TNF-α is important for walling off infection and
preventing dissemination. Convincing data on the
importance of this cytokine in granuloma formation
in TB and other mycobacterial diseases has been
reported123,125. TNF-α affects cell migration and
localization within tissues in M. tuberculosis
infection.  TNF-α influence expression of adhesion
molecules as well as chemokines and chemokine
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receptors, and this is certain to affect the formation
of functional granuloma in infected tissues.
TNF-α has also been implicated in
immunopathologic response and is often a major
factor in host-mediated destruction of lung tissue126.
In our studies, increased level of TNF-α was found
at the site of lesion (pleural fluid), as compared to
systemic response (blood) showing that the
compartmentalized immune response must be
containing the infection127.
Interleukin-1: IL-1, along with TNF-α, plays an
important role in the acute phase response such as
fever and cachexia, prominent in TB.  In addition,
IL-1 facilitates  T lymphocyte expression of IL-2
receptors and IL-2 release. The major antigens of
mycobacteria triggering IL-1 release and TNF-α have
been identified128. IL-1 has been implicated in
immunosuppressive mechanisms which is an
important feature in tuberculoimmunity129.
Interleukin-2: IL-2 has a pivotal role in generating
an immune response by inducing an expansion of the
pool of lymphocytes specific for an antigen.
Therefore, IL-2 secretion by the protective CD4 Th1
cells is an important parameter to be measured and
several studies have demonstrated that IL-2 can
influence the course of mycobacterial infections,
either alone or in combination with other cytokines130.
Interleukin-4: Th2 responses and IL-4 in TB are
subjects of some controversy.  In human studies, a
depressed Th1 response, but not an enhanced Th2
response was observed in PBMC from TB
patients107,118.  Elevated IFN-γ expression was
detected in granuloma within lymph nodes of patients
with tuberculous lymphadenitis, but little IL-4 mRNA
was detected107.  These results indicated that in
humans a strong Th2 response is not associated with
TB.  Data from mice studies116 suggest that the
absence of a Th1 response to M. tuberculosis does
not necessarily promote a Th2 response and an IFN-
γ deficiency, rather than the presence of IL-4 or other
Th2 cytokines, prevents control of infection.  In a
study of cytokine gene expression in the granuloma
of patients with advanced TB by in situ hybridization,
IL-4 was detected in 3 of 5 patients, but never in the
absence of IFN-γ expression131.  The presence or
absence of IL-4 did not correlate with improved
clinical outcome or differences in granuloma stages
or pathology.
Interleukin-6: IL-6 has also been implicated in the
host response to M. tuberculosis.  This cytokine has
multiple roles in the immune response, including
inflammation, hematopoiesis and differentiation of
T cells.  A potential role for IL-6 in suppression of T
cell responses was reported41.  Early increase in lung
burden in IL-6 -/- mice suggests that IL-6 is important
in the initial innate response to the pathogen132.
Interleukin-10: IL-10 is considered to be an anti-
inflammatory cytokine.  This cytokine, produced by
macrophages and T cells during M. tuberculosis
infection, possesses macrophage-deactivating
properties, including downregulation of IL-12
production, which in turn decreases IFN-γ production
by T cells.  IL-10 directly inhibits CD4+ T cell
responses, as well as by inhibiting APC function of
cells infected with mycobacteria133.  Transgenic mice
constitutively expressing IL-10 were less capable of
clearing a BCG infection, although T cell responses
including IFN-γ production were unimpaired134.
These results suggested that IL-10 might counter the
macrophage activating properties of IFN-γ.
Transforming growth factor-beta (TGF-β): TGF-β is
present in the granulomatous lesions of TB patients
and is produced by human monocytes after
stimulation with M. tuberculosis135 or
lipoarabinomannan136.  TGF-β has important anti-
inflammatory effects, including deactivation of
macrophage production of  ROI and RNI137, inhibition
of T cell proliferation40, interference with NK and
CTL function and downregulation of IFN-γ, TNF-α
and IL-1 release138.  Toossi et al135 have shown that
when TGF-β is added to co-cultures of mononuclear
phagocytes and M. tuberculosis, both phagocytosis
and growth inhibition were inhibited in a dose-
dependent manner.  Part of the ability of macrophages
to inhibit mycobacterial growth may depend on the
relative influence of IFN-γ and TGF-β in any given
focus of infection.
Cell migration and granuloma formation
A successful host inflammatory response to
invading microbes requires precise coordination of
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myriad immunologic elements.  An important first
step is to recruit intravascular immune cells to the
proximity of the infective focus and prepare them
for extravasation.  This is controlled by adhesion
molecules and chemokines.  Chemokines contribute
to cell migration and localization, as well as affect
priming and differentiation of T cell responses139.
Granuloma: CD4+ T cells are prominent in the
lymphocytic layer surrounding the granuloma and
CD8+ T cells are also noted140. In mature granulomas
in humans, dendritic cells displaying long filopodia
are seen interspersed among epithelioid cells.
Apoptosis is prominent in the epithelioid cells32.
Proliferation of mycobacteria in situ occurs in both
the lymphocyte and macrophage derived cells in the
granuloma141.  Heterotypic and homotypic cell
adhesion in the developing granuloma is mediated at
least in part by the intracellular adhesion molecule
(ICAM-1), a surface molecule that is up regulated
by  M. tuberculosis or LAM142.  The differentiated
epithelioid cells produce extracellular matrix proteins
(i.e., osteopontin, fibronectin), that provide a cellular
anchor through integrin molecules143.
In our experience144, the lymph node biopsy
specimens showing histological evidence of TB could
be classified into four groups based on the organization
of the granuloma, the type and numbers of participating
cells and the nature of necrosis. These were (i)
hyperplastic (22.4%) - a well-formed epithelioid cell
granuloma with very little necrosis; (ii) reactive (54.3%)
- a well-formed granuloma consisting of epithelioid
cells, macrophages, lymphocytes and plasma cells with
fine, eosinophilic caseation necrosis; (iii) hyporeactive
(17.7%) - a poorly organized granuloma with
macrophages, immature epithelioid cells, lymphocytes
and plasma cells and coarse, predominantly basophilic
caseation necrosis; and (iv) nonreactive (3.6%) -
unorganized granuloma with macrophages,
lymphocytes, plasma cells and polymorphs with non
caseating necrosis. It is likely that the spectrum of
histological responses seen in tuberculous lymphadenitis
is the end result of different pathogenic mechanisms
underlying the disease144.
Chemokines: The interaction of macrophages with
other effector cells occurs in the milieu of both
cytokines and chemokines.  These molecules serve
both to attract other inflammatory effector cells such
as lymphocytes and to activate them.
Interleukin-8: An important chemokine in the
mycobacterial host-pathogen interaction appears to
be IL-8.  It recruits neutrophils, T lymphocytes, and
basophils in response to a variety of stimuli.  It is
released primarily by monocytes/macrophages, but
it can also be expressed by fibroblasts, keratinocytes,
and lymphocytes145.  IL-8 is the neutrophil activating
factor.
Elevated levels of IL-8 in BAL fluid and
supernatants from alveolar macrophages were seen
in patients140.  IL-8 gene expression was also
increased in the macrophages as compared with those
in normal control subjects.  In a series of in vitro
experiments it was also demonstrated that intact M.
tuberculosis or LAM, but not deacylated LAM, could
stimulate IL-8 release from macrophages146.
Friedland et al147 studied a group of mainly HIV-
positive patients, and reported that both plasma IL-8
and secretion of IL-8 after ex vivo stimulation of
peripheral blood leukocytes with lipopolysaccharide
remained elevated throughout therapy for TB.  Other
investigators had previously shown that IL-8 was also
present at other sites of disease, such as the pleural
space in patients with TB pleurisy148.
Other chemokines: Other chemokines that have been
implicated in the host response to TB include
monocyte chemoattractant protein-1 (MCP-1) and
regulated on activation normal T cell expressed and
secreted (RANTES), which both decrease in the
convalescent phase of treatment, as opposed to IL-8.
Chemokine and chemokine receptor expression must
contribute to the formation and maintenance of
granuloma in chronic infections such as TB.  In in
vitro and in vivo murine models, M. tuberculosis
induced production of a variety of chemokines,
including RANTES, macrophage inflammatory
protein1-α (MIP-α), MIP2, MCP-1, MCP-3, MCP-5
and IP10149.  Mice over expressing MCP-1150, but not
MCP-/- mice151, were more susceptible to
M. tuberculosis infection than were wild type mice.
C-C chemokine receptor 2 (CCR2) is a receptor for
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MCP-1, 3 and 5 and is present on macrophages and
activated T cells.  CCR2-/- mice are extraordinarily
susceptible to M. tuberculosis infection and they
exhibit a defect in macrophage recruitment to the
lungs. The current literature indicates that TNF-α can
upregulate expression of MIP1-α, MIP1-β, MIP2,
MCP-1, cytokine-induced neutrophil chemoattractant
(CINC) and RANTES152, and it can affect recruitment
of neutrophils, lymphocytes and monocytes/
macrophages to certain sites.
RANTES, MCP-1, MIP1-α and IL-8 were released
by human alveolar macrophages upon infection with
M. tuberculosis in vitro153 and monocytes, lymph
node cells and BAL fluid from pulmonary TB patients
had increased levels of a subset of these chemokines
compared to healthy controls153,154.  In human studies,
CCR5, the receptor for RANTES, MIP-α and MIP-
β, was increased on macrophages following in vitro
M. tuberculosis  infection and on alveolar
macrophages in BAL from TB patients155.
HIV-TB coinfection
Studies from many parts of the world have shown
higher incidence of TB among HIV infected
individuals, ranging from 5 to 10 per year of
observation156, which is in sharp contrast to the
lifetime risk of 10 per cent among people without
HIV.  Persons with HIV infection are at increased
risk of rapid progression of a recently acquired
infection, as well as of re-activation of latent
infection. TB is the commonest opportunistic
infection occurring among HIV-positive persons in
India and studies from different parts of the country
have estimated that 60 to 70 per cent of HIV positive
patients will develop TB in their lifetime157.
Differences in HIV-positive TB, as opposed to HIV-
negative TB, include a higher proportion of cases with
extra-pulmonary or disseminated disease, a higher
frequency of false-negative tuberculin skin tests,
atypical features on chest radiographs, fewer
cavitating lung lesions, a higher rate of adverse drug
reactions, the presence of other AIDS-associated
manifestations and a higher death rate.
TB and HIV infections are both intracellular and
known to have profound influence on the progression
of each other.  HIV infection brings about the
reduction in CD4+ T cells, which play a main role in
immunity to TB.  This is reflected in the integrity of
the cellular immune response, namely the granuloma.
Apart from the reduction in number, HIV also causes
functional abnormality of CD4+ and CD8+ cells.
Likewise, TB infection also accelerates the
progression of HIV disease from asymptomatic
infection to AIDS to death.  A potent activator of
HIV replication within T cells is TNF-α, which is
produced by activated macrophages within granuloma
as a response to tubercle infection158. Because the
clinical features of HIV infected patients with TB
are often non specific, diagnosis can be difficult.  The
method most widely used, detection of acid-fast
bacilli by microscopic examination of sputum smears,
is of little use, since 50 per cent of the HIV-TB cases
are negative by acid fast staining159. Chest radiograph
is normal in up to 10-20 per cent of patients with
AIDS160. Alternative diagnostic tests, based on
serology, using crude mycobacterial antigens161,
purified lipid162 and protein antigens163, have been
tried with varying results. Our results with purified
38, 30, 16 and 27kDa antigens to study the antibody
response to different isotypes have yielded an
improved sensitivity and specificity67,68.
Since the CD4+ receptors of the T cells are bound
by the HIV through the gp120 antigen, interaction of
these cells with APC presenting antigen in the context
of Class II MHC molecules is impaired, which results
in hypo-responsiveness to soluble tubercle antigens.
HIV infection also downregulates the Th1 response,
not affecting or increasing the Th2 response. In
patients co-infected with TB and HIV, expression of
IFN-γ, IL-2 and IL-4 in PBMCs is suppressed, but
IL-10 levels do not differ from patients with HIV
infection164.  The suppressed Th1 response paves the
way for susceptibility to many intracellular
infections. A role for NK cells also has been
implicated in the immune response to HIV. It has
been reported that NK cells from normal and HIV
positive donors produce C-C chemokines and other
factors that can inhibit both macrophage and T cell
tropic HIV replication in vitro165.  Another group
reported a decline in NK activity, which strongly
correlated with the disease progression in HIV
patients166.  Our studies demonstrate that even though
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there is no difference in the per cent of NK cells,
there is lowered NK activity during TB and HIV-TB
infection54.
Though most patients respond very well to
antituberculous treatment initially, they develop other
opportunistic infections and deteriorate rapidly
within a few months. Further, recurrence of TB is
more frequent than in immunocompetent population,
due to both endogenous reactivation or exogenous
reinfection.
Immunogenetics of TB
Yet another important area in understanding the
immunology of TB is host genetics, which is briefly
discussed here. Susceptibility to TB is multifactorial.
Finding out the host genetic factors such as human
leucocyte antigens (HLA) and non-HLA genes/
gene products that are associated with the
susceptibility to TB will serve as genetic markers to
understand predisposition to the development of the
disease.
A number of studies on host genetics have been
carried out in our laboratory. Our studies on HLA in
pulmonary TB patients and their spouses revealed
the association of HLA-DR2 (subtype DRB1*1501)
and -DQ1 antigens with the susceptibility to
pulmonary TB167,168.  Further studies on various non-
HLA gene polymorphisms such as mannose binding
lectin (MBL)169, vitamin D receptor (VDR)170,171,
TNF-α  and β172, IL-1 receptor antagonist170 and
Nramp45 genes revealed that functional mutant
homozygotes (FMHs) of MBL are associated with
the susceptibility to pulmonary TB.  The polymorphic
BsmI, ApaI, TaqI and FokI gene variants of VDR
showed differential susceptibility or resistance with
male or female subjects.  These studies suggest that
multicandidate genes are associated with the
susceptibility to pulmonary TB.
The role of HLA-DR2 and the variant genotypes
of MBL on the immunity to TB revealed that in a
susceptible host (HLA-DR2, FMHs of MBL-positive
subjects) the innate immunity (lysozyme, mannose
binding lectin, etc.) play an important role173-176. If
the innate immunity fails, HLA-DR2 plays an
important role on the specific immune response
against the pathogen.
Conclusion
The protective and pathologic response of host to
M. tuberculosis  is complex and multifaceted,
involving many components of the immune system.
Because of this complexity, it becomes extremely
difficult to identify the mechanism(s) involved in
protection and design surrogate markers to be
measured as in vitro correlate of protective immunity.
A clear picture of the network of immune responses
to this pathogen, as well as an understanding of the
effector functions of these components, is essential
to the design and implementation of effective
vaccines and treatments for TB.  The combination of
studies in animal models and human subjects, as well
as technical advances in genetic manipulation of the
organism, will be instrumental in enhancing our
understanding of this immensely successful pathogen
in the future.
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